双歧杆菌四联活菌片联合富马酸替诺福韦治疗乙肝肝纤维化的疗效  

Therapeutic Effect of Bifidobacterium Tetramethyl-viable Tablets Combined with Tenofovir Fumarate on Hepatitis B Liver Fibrosis

作　　者：袁方 张霞 李俊红 YUAN Fang;ZHANG Xia;LI Jun-hong(Department of Infectious Diseases,Xuchang People's Hospital,Xuchang 461000,Henan Province,China)

机构地区：[1]许昌市人民医院感染性疾病科,河南许昌461000

出　　处：《罕少疾病杂志》2024年第6期68-70,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的 探讨双歧杆菌四联活菌片联合富马酸替诺福韦治疗乙肝肝纤维化的疗效。方法 选取2020年6月至2023年2月在本院就诊的乙肝肝纤维化患者60例,对照组在常规对症治疗的基础上接受富马酸替诺福韦进行治疗,观察组在对照组的基础上接受双歧杆菌四联活菌片进行治疗,统计两组患者肝功能指标、肝纤维化指标、炎性指标、影像学指标、肠黏膜屏障功能、不良反应发生率。结果 治疗前,两组患者ALT、AST、TBIL、ALB比较,差异均无统计学意义(P>0.05),治疗6月后,两组患者ALT、AST均较治疗前明显下降,TBIL、ALB均较治疗前无明显变化,组间比较,观察组患者ALT、AST低于对照组患者,差异具有统计学意义(P<0.05),两组TBIL、ALB比较,差异无统计学意义(P>0.05);治疗前,两组患者肝纤维化指标比较,差异均无统计学意义(P>0.05),治疗6月后,两组患者肝纤维化指标均较治疗前明显下降,组间比较,观察组患者HA、LN、PCⅢ、Ⅳ-C低于对照组患者,差异具有统计学意义(P<0.05);治疗前,两组患者炎性指标比较,差异均无统计学意义(P>0.05),治疗6月后,两组患者炎性指标均较治疗前明显下降,组间比较,观察组患者MMP-13、TNF-α、TGF-β1低于对照组患者,差异具有统计学意义(P<0.05);治疗前,两组患者影像学指标比较,差异均无统计学意义(P>0.05),治疗6月后,两组患者影像学指标门静脉直径、脾肿指数均较治疗前明显下降,右肝斜径较治疗前无明显变化,组间比较,观察组患者门静脉直径、脾肿指数低于对照组患者,差异具有统计学意义(P<0.05),两组右肝斜径比较,差异无统计学意义(P>0.05);治疗前,两组患者肠黏膜屏障功能指标比较,差异均无统计学意义(P>0.05),治疗6月后,两组患者肠黏膜屏障功能指标均较治疗前明显下降,组间比较,观察组患者指标低于对照组,差异具有统计学意义(P<0.05);观察组患者不良反应发生率10.00Objective To investigate the curative effect of bifidobacterium quadruplex viable tablets combined with tenofovir fumarate on hepatitis B liver fibrosis.MethodSixty patients with hepatitis B liver fibrosis who were admitted to our hospital from June 2020 to February 2023 were selected and given tenofovir fumarate+conventional symptomatic treatment according to the group,while the observation group was given bifidobacterium quadruplex viable tablet+tenofovir fumarate+conventional symptomatic treatment.Liver function indexes,liver fibrosis indexes,inflammatory indexes,imaging indexes,intestinal mucosal barrier function,and incidence of adverse reactions were analyzed in the two groups.ResultsAfter 6 months of treatment,ALT and AST in the observation group were lower than those in the control group(P<0.05),and TBIL and ALB were compared between the two groups,P>0.05;HA,LN,PCⅢandⅣ-C in observation group were lower than those in control group(P<0.05).MMP-13,TNF-αand TGF-β1 in observation group were lower than those in control group(P<0.05);The portal vein diameter and spleen swelling index in observation group were lower than those in control group(P<0.05),and the oblique diameter of right liver between the two groups was compared,P>0.05.The incidence of adverse reactions in observation group was 10.00%lower than that in control group(P<0.05).ConclusionsBifidobacterium tetracomovir combined with tenofovir fumarate in the treatment of hepatitis B liver fibrosis patients can promote the recovery of liver function and intestinal mucosal function of patients,improve liver fibrosis,control inflammatory response,and have high safety,which is conducive to promoting the outcome of the disease.

关 键 词：双歧杆菌四联活菌片 富马酸替诺福韦 乙肝肝纤维化 肝功能 肝纤维化 炎症反应 安全性 

分 类 号：R575.1[医药卫生—消化系统]